<?xml version="1.0" encoding="UTF-8"?>
<p>Lopinavir/ritonavir and disulfiram are the well‐known viral protease inhibitors and have been shown to be effective against SARS and MERS.
 <xref rid="jcmm15364-bib-0076" ref-type="ref">
  <sup>76</sup>
 </xref> Lopinavir/ritonavir were reported to reduce mortality, intubation rate and the use of methylprednisolone when introduced as a treatment of SARS patients in early stage.
 <xref rid="jcmm15364-bib-0076" ref-type="ref">
  <sup>76</sup>
 </xref>, 
 <xref rid="jcmm15364-bib-0077" ref-type="ref">
  <sup>77</sup>
 </xref> A recent study reported two COVID‐19 cases in South Korea and found that they did not have a significant decrease of the viral load after lopinavir/ritonavir therapy, but experienced gastrointestinal discomfort as a side effect.
 <xref rid="jcmm15364-bib-0078" ref-type="ref">
  <sup>78</sup>
 </xref> Recent published result of the first clinical trial for lopinavir/ritonavir indicated that no benefit effect was observed after lopinavir/ritonavir treatment beyond standard care in hospitalized severe COVID‐19 patients.
 <xref rid="jcmm15364-bib-0079" ref-type="ref">
  <sup>79</sup>
 </xref> Disulfiram is a drug for the treatment of alcohol dependence, and studies have confirmed its inhibitory activity against SARS and MERS in cell cultures instead of clinical situation.
 <xref rid="jcmm15364-bib-0072" ref-type="ref">
  <sup>72</sup>
 </xref>
</p>
